Evidence map›Paper›PMID 28096141›Full record

ReviewAdvances in nutrition (Bethesda, Md.)2017

The Role of the Novel Lipokine Palmitoleic Acid in Health and Disease.

María E Frigolet, Ruth Gutiérrez-Aguilar

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Advances in nutrition (Bethesda, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03625427 (Effects of Palmitoleic Acid on Circulating C-reactive Protein Levels in Humans), which is not on this map. Cited by 113 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 1 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03625427 nacompletednot on this mapstarted 2019, after this paper: background citation

Effects of Palmitoleic Acid on Circulating C-reactive Protein Levels in Humans

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2019 to 2022Enrolled123ConditionsChronic Inflammation, OverweightArmsPlacebo, Palmitoleic acid, 500 mg (Dose 1), Palmitoleic acid, 1,000 mg (Dose 2)
3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 1 synthesis or guideline pooled it, 249 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Maternal obesity results in decreased syncytiotrophoblast synthesis of palmitoleic acid, a fatty acid with anti-inflammatory and insulin-sensitizing properties.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Trial
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Chemical Profiling andNutrients · 2026
    Article
  14. Advances in Adipose Tissue Biology.Endocrine reviews · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

María E FrigoletMetabolic Diseases: Obesity and Diabetes Laboratory, Hospital Infantil de México Federico Gómez, Mexico City, Mexico; and maruf.himfg@gmail.com.
Ruth Gutiérrez-AguilarMetabolic Diseases: Obesity and Diabetes Laboratory, Hospital Infantil de México Federico Gómez, Mexico City, Mexico; and.
Hospital Infantil de México Federico Gómez · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The monounsaturated fatty acid palmitoleate (palmitoleic acid) is one of the most abundant fatty acids in serum and tissues, particularly adipose tissue and liver. Its endogenous production by stearoyl-CoA desaturase 1 gives rise to its cis isoform, cis-palmitoleate. Although trans-palmitoleate is also synthesized in humans, it is mainly found as an exogenous source in ruminant fat and dairy products. Recently, palmitoleate was considered to be a lipokine based on evidence demonstrating its release from adipose tissue and its metabolic effects on distant organs. After this finding, research has been performed to determine whether palmitoleate has beneficial effects on metabolism and to elucidate the underlying mechanisms. Thus, the aim of this work was to review the current status of knowledge about palmitoleate, its metabolism, and its influence on metabolic abnormalities. Results have shown mixed cardiovascular effects, direct or inverse correlations with obesity, and hepatosteatosis, but a significant amelioration or prevention of insulin resistance and diabetes. Finally, the induction of palmitoleate release from adipose tissue, dietary intake, and its supplementation are all interventions with a potential impact on certain metabolic diseases.

Indexed as

DietAdipokinesAdipose TissueAnimalsDiabetes MellitusDietary FatsDietary SupplementsFatty Acids, MonounsaturatedFatty LiverHumansInsulin ResistanceMetabolic DiseasesObesityAdipokinesDietary FatsFatty Acids, Monounsaturatedpalmitoleic acidcardiovascular diseasediabetesdietfatty acidsinsulin resistancelipokineobesitypalmitoleate

Identifiers

PMID28096141
PMCPMC5227969
OpenAlexW2571799777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.